Grahaem Brown has been appointed director of development at Celltech. Brown previously worked in drug development for 20 years at Pfizer, Pharmacia, Novartis, and GlaxoSmithKline. Prior to that, he worked in hospital medicine for 10 years, including two years in Malaysia. He is qualified in medicine at University College Hospital in London, and has been accredited in internal and tropical medicine.
Patrick Round, previous director of development at Celltech, has become global director for CDP 870.
Andrew Bodnar, Edward Scolnick, George Daley, and Bennett Shapiro have been appointed to the newly formed clinical advisory board at Elixir Pharmaceuticals. Bodnar is senior vice president, strategy and medical & external affairs at Bristol-Myers Squibb. Prior to joining Bristol-Myers Squibb, he was associate chief of internal medicine, acting chief of cardiology, and director of the internal medicine residency program at Massachusetts General Hospital in Boston.
Edward Scolnick is president emeritus at Merck Research Labs. Before joining Merck, he was chief of the laboratory of tumor virus genetics at the National Cancer Institute.
George Daley is a partner at venture firm MPM Capital, as well as the firm’s chief medical and scientific advisor. He is also an associate professor of biological chemistry and molecular pharmacology and pediatrics at Harvard Medical School, and a staff member in hematology/oncology at the Children’s Hospital, Dana Farber Cancer Institute, and Brigham and Women’s Hospital. Previously, Daley was Whitehead Fellow at the Whitehead Institute for Biomedical Research and assistant professor of medicine at Harvard Medical School and the Massachusetts General Hospital.
Bennett Shapiro retired this year from Merck Research Labs, where he was senior vice president, worldwide licensing and external scientific affairs. He was previously vice president of basic research at MRL, and prior to that, was professor and chairman of the department of biochemistry at the University of Washington.